. 2014 Aug; 20(4):256-61.
doi: 10.1097/PPO.0000000000000061.

Inducible expression of B7-H1 (PD-L1) and its selective role in tumor site immune modulation

Miguel F Sanmamed 1 Lieping Chen  
  • PMID: 25098285
  •     50 References
  •     62 citations


Immune evasion is an important hallmark of cancer, and a better understanding of this mechanism is essential for the development of effective strategies against cancer. The B7 homolog 1 (B7-H1)/programmed cell death 1 (PD-1) pathway has been demonstrated as a major mechanism of immune evasion in tumor site, and its blockade therapy shows very encouraging results in clinical trials. Inducible B7-H1 expression in tumor microenvironment is complex, with multidimensional interactions and expression by different subsets of hematopoietic and nonhematopoietic cells. Understanding these interactions and how tumors take advantage of this pathway can help us design future strategies for better therapeutic efficacy and to overcome resistances.

Restoring function in exhausted CD8 T cells during chronic viral infection.
Daniel L Barber, E John Wherry, +5 authors, Rafi Ahmed.
Nature, 2005 Dec 31; 439(7077). PMID: 16382236
Highly Cited.
PD-L1 expression in triple-negative breast cancer.
Elizabeth A Mittendorf, Anne V Philips, +14 authors, Gheath Alatrash.
Cancer Immunol Res, 2014 Apr 26; 2(4). PMID: 24764583    Free PMC article.
Highly Cited.
B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance.
Jang-June Park, Ryusuke Omiya, +11 authors, Koji Tamada.
Blood, 2010 May 18; 116(8). PMID: 20472828    Free PMC article.
Highly Cited.
B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells.
Takeshi Azuma, Sheng Yao, +3 authors, Lieping Chen.
Blood, 2008 Jan 29; 111(7). PMID: 18223165    Free PMC article.
Highly Cited.
Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs.
Raymond M Wong, Ron R Scotland, +4 authors, Jeffrey S Weber.
Int Immunol, 2007 Sep 28; 19(10). PMID: 17898045
Characterization of human lung tumor-associated fibroblasts and their ability to modulate the activation of tumor-associated T cells.
Michael R Nazareth, Lori Broderick, +3 authors, Richard B Bankert.
J Immunol, 2007 Apr 20; 178(9). PMID: 17442937
Programmed death ligand-1 expression in non-small cell lung cancer.
Vamsidhar Velcheti, Kurt A Schalper, +7 authors, David L Rimm.
Lab Invest, 2013 Nov 13; 94(1). PMID: 24217091    Free PMC article.
Highly Cited.
Nivolumab plus ipilimumab in advanced melanoma.
Jedd D Wolchok, Harriet Kluger, +21 authors, Mario Sznol.
N Engl J Med, 2013 Jun 04; 369(2). PMID: 23724867    Free PMC article.
Highly Cited.
Management of immune-related adverse events and kinetics of response with ipilimumab.
Jeffrey S Weber, Katharina C Kähler, Axel Hauschild.
J Clin Oncol, 2012 May 23; 30(21). PMID: 22614989
Highly Cited. Review.
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.
Omid Hamid, Caroline Robert, +23 authors, Antoni Ribas.
N Engl J Med, 2013 Jun 04; 369(2). PMID: 23724846    Free PMC article.
Highly Cited.
B7-H1-induced apoptosis as a mechanism of immune privilege of corneal allografts.
Junko Hori, Mingcong Wang, +6 authors, Miyuki Azuma.
J Immunol, 2006 Oct 24; 177(9). PMID: 17056517
Programmed death-1-induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection.
Elias A Said, Franck P Dupuy, +16 authors, Rafick-Pierre Sekaly.
Nat Med, 2010 Mar 09; 16(4). PMID: 20208540    Free PMC article.
Highly Cited.
Hepatotoxicity with combination of vemurafenib and ipilimumab.
Antoni Ribas, F Stephen Hodi, +2 authors, Jedd Wolchok.
N Engl J Med, 2013 Apr 05; 368(14). PMID: 23550685
Highly Cited.
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.
Antoni Ribas, Richard Kefford, +21 authors, Axel Hauschild.
J Clin Oncol, 2013 Jan 09; 31(5). PMID: 23295794    Free PMC article.
Highly Cited.
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
Julie R Brahmer, Scott S Tykodi, +23 authors, Jon M Wigginton.
N Engl J Med, 2012 Jun 05; 366(26). PMID: 22658128    Free PMC article.
Highly Cited.
Improved survival with ipilimumab in patients with metastatic melanoma.
F Stephen Hodi, Steven J O'Day, +26 authors, Walter J Urba.
N Engl J Med, 2010 Jun 08; 363(8). PMID: 20525992    Free PMC article.
Highly Cited.
Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells.
Mark J Selby, John J Engelhardt, +4 authors, Alan J Korman.
Cancer Immunol Res, 2014 Apr 30; 1(1). PMID: 24777248
Highly Cited.
PD-1 and its ligands in tolerance and immunity.
Mary E Keir, Manish J Butte, Gordon J Freeman, Arlene H Sharpe.
Annu Rev Immunol, 2008 Jan 05; 26. PMID: 18173375
Highly Cited. Review.
The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination?
Craig L Slingluff.
Cancer J, 2011 Sep 29; 17(5). PMID: 21952285    Free PMC article.
Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape.
Janis M Taube, Robert A Anders, +8 authors, Lieping Chen.
Sci Transl Med, 2012 Mar 31; 4(127). PMID: 22461641    Free PMC article.
Highly Cited.
Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-gamma-induced upregulation of B7-H1 (CD274).
Seung-Jin Lee, Byeong-Churl Jang, +8 authors, In-Hak Choi.
FEBS Lett, 2006 Jan 18; 580(3). PMID: 16413538
Highly Cited.
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Suzanne L Topalian, F Stephen Hodi, +27 authors, Mario Sznol.
N Engl J Med, 2012 Jun 05; 366(26). PMID: 22658127    Free PMC article.
Highly Cited.
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors.
Michael A Curran, Welby Montalvo, Hideo Yagita, James P Allison.
Proc Natl Acad Sci U S A, 2010 Feb 18; 107(9). PMID: 20160101    Free PMC article.
Highly Cited.
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.
G J Freeman, A J Long, +16 authors, T Honjo.
J Exp Med, 2000 Oct 04; 192(7). PMID: 11015443    Free PMC article.
Highly Cited.
RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance.
Yanping Xiao, Sanhong Yu, +9 authors, Gordon J Freeman.
J Exp Med, 2014 Apr 23; 211(5). PMID: 24752301    Free PMC article.
Highly Cited.
Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4.
P Waterhouse, J M Penninger, +6 authors, T W Mak.
Science, 1995 Nov 10; 270(5238). PMID: 7481803
Highly Cited.
The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors.
Hazem Ghebeh, Shamayel Mohammed, +10 authors, Said Dermime.
Neoplasia, 2006 Apr 14; 8(3). PMID: 16611412    Free PMC article.
Highly Cited.
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity.
Tyler J Curiel, Shuang Wei, +19 authors, Weiping Zou.
Nat Med, 2003 Apr 22; 9(5). PMID: 12704383
Highly Cited.
Inhibitory B7-family molecules in the tumour microenvironment.
Weiping Zou, Lieping Chen.
Nat Rev Immunol, 2008 May 27; 8(6). PMID: 18500231
Highly Cited. Review.
Preclinical evidence that PD1 blockade cooperates with cancer vaccine TEGVAX to elicit regression of established tumors.
Juan Fu, Ian-James Malm, +3 authors, Young J Kim.
Cancer Res, 2014 May 09; 74(15). PMID: 24812273    Free PMC article.
CTLA-4 control over Foxp3+ regulatory T cell function.
Kajsa Wing, Yasushi Onishi, +5 authors, Shimon Sakaguchi.
Science, 2008 Oct 11; 322(5899). PMID: 18845758
Highly Cited.
B7-H1 (programmed death-1 ligand) on dendritic cells is involved in the induction and maintenance of T cell anergy.
Nicole Selenko-Gebauer, Otto Majdic, +9 authors, Johannes Stöckl.
J Immunol, 2003 Mar 21; 170(7). PMID: 12646628
Cancer vaccines: Looking to the future.
Kavitha Yaddanapudi, Robert A Mitchell, John W Eaton.
Oncoimmunology, 2013 Jun 27; 2(3). PMID: 23802081    Free PMC article.
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses.
Manish J Butte, Mary E Keir, +2 authors, Gordon J Freeman.
Immunity, 2007 Jul 17; 27(1). PMID: 17629517    Free PMC article.
Highly Cited.
Cutting edge: IFN-gamma enables APC to promote memory Th17 and abate Th1 cell development.
Ilona Kryczek, Shuang Wei, +6 authors, Weiping Zou.
J Immunol, 2008 Oct 23; 181(9). PMID: 18941172
Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma.
Rezaul Karim, Ekaterina S Jordanova, +5 authors, Sjoerd H van der Burg.
Clin Cancer Res, 2009 Oct 15; 15(20). PMID: 19825956
Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer--response.
Mario Sznol, Lieping Chen.
Clin Cancer Res, 2013 Sep 21; 19(19). PMID: 24048329    Free PMC article.
B7-H1 is expressed by human endothelial cells and suppresses T cell cytokine synthesis.
Melissa M Mazanet, Christopher C W Hughes.
J Immunol, 2002 Sep 24; 169(7). PMID: 12244148
Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes.
Ching-Yao Yang, Mong-Wei Lin, +2 authors, Pan-Chyr Yang.
Eur J Cancer, 2014 Feb 20; 50(7). PMID: 24548766
Highly Cited.
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion.
Haidong Dong, Scott E Strome, +10 authors, Lieping Chen.
Nat Med, 2002 Jul 02; 8(8). PMID: 12091876
Highly Cited.
Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2.
Tadashi Yokosuka, Masako Takamatsu, +3 authors, Takashi Saito.
J Exp Med, 2012 May 30; 209(6). PMID: 22641383    Free PMC article.
Highly Cited.
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.
Tyler R Simpson, Fubin Li, +11 authors, Sergio A Quezada.
J Exp Med, 2013 Jul 31; 210(9). PMID: 23897981    Free PMC article.
Highly Cited.
Progress in human tumour immunology and immunotherapy.
S A Rosenberg.
Nature, 2001 May 18; 411(6835). PMID: 11357146
Highly Cited. Review.
B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion.
H Dong, G Zhu, K Tamada, L Chen.
Nat Med, 1999 Dec 02; 5(12). PMID: 10581077
Highly Cited.
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma.
Andrew T Parsa, James S Waldron, +10 authors, Russell O Pieper.
Nat Med, 2006 Dec 13; 13(1). PMID: 17159987
Highly Cited.
B7-H1 is up-regulated in HIV infection and is a novel surrogate marker of disease progression.
Daria Trabattoni, Marina Saresella, +8 authors, Mario Clerici.
Blood, 2002 Dec 07; 101(7). PMID: 12468426
Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity.
Fumiya Hirano, Katsumi Kaneko, +9 authors, Lieping Chen.
Cancer Res, 2005 Feb 12; 65(3). PMID: 15705911
Highly Cited.
B7-H1 determines accumulation and deletion of intrahepatic CD8(+) T lymphocytes.
Haidong Dong, Gefeng Zhu, +3 authors, Lieping Chen.
Immunity, 2004 Mar 20; 20(3). PMID: 15030776
Highly Cited.
Mechanisms of immune evasion by tumors.
Charles G Drake, Elizabeth Jaffee, Drew M Pardoll.
Adv Immunol, 2006 May 30; 90. PMID: 16730261
Highly Cited. Review.
Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.
Esra A Akbay, Shohei Koyama, +24 authors, Kwok-Kin Wong.
Cancer Discov, 2013 Oct 01; 3(12). PMID: 24078774    Free PMC article.
Highly Cited.
Targeting the PD-1/PD-L1 Immune Evasion Axis With DNA Aptamers as a Novel Therapeutic Strategy for the Treatment of Disseminated Cancers.
Aaron Prodeus, Aws Abdul-Wahid, +3 authors, Jean Gariépy.
Mol Ther Nucleic Acids, 2015 Apr 29; 4. PMID: 25919090    Free PMC article.
Potential biomarker for checkpoint blockade immunotherapy and treatment strategy.
Zhong-Yi Dong, Si-Pei Wu, +2 authors, Yi-Long Wu.
Tumour Biol, 2016 Jan 19; 37(4). PMID: 26779629
The prevalence and clinicopathological features of programmed death-ligand 1 (PD-L1) expression: a pooled analysis of literatures.
Ziying Lin, Yutong Xu, +4 authors, Wenhua Liang.
Oncotarget, 2016 Mar 02; 7(12). PMID: 26930715    Free PMC article.
EML4-ALK enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor (HIF)-1α and STAT3.
Jaemoon Koh, Ji-Young Jang, +8 authors, Doo Hyun Chung.
Oncoimmunology, 2016 May 04; 5(3). PMID: 27141364    Free PMC article.
A meta-analysis reveals prognostic role of programmed death ligand-1 in Asian patients with non-small cell lung cancer.
Xiao-Yan Hu, Wei Zhang, +4 authors, Li Liu.
J Huazhong Univ Sci Technolog Med Sci, 2016 Jul 05; 36(3). PMID: 27376797
Classification of Advanced Human Cancers Based on Tumor Immunity in the MicroEnvironment (TIME) for Cancer Immunotherapy.
Yu Zhang, Lieping Chen.
JAMA Oncol, 2016 Aug 05; 2(11). PMID: 27490017    Free PMC article.
Predictive factors of the tumor immunological microenvironment for long-term follow-up in early stage breast cancer.
Mina Okabe, Uhi Toh, +8 authors, Yoshito Akagi.
Cancer Sci, 2016 Nov 02; 108(1). PMID: 27801993    Free PMC article.
The clinicopathological and prognostic significance of PD-L1 expression in gastric cancer: a meta-analysis of 10 studies with 1,901 patients.
Minghui Zhang, Yuandi Dong, +5 authors, Qingyuan Zhang.
Sci Rep, 2016 Nov 29; 6. PMID: 27892511    Free PMC article.
PD-1 and its ligands are important immune checkpoints in cancer.
Yinan Dong, Qian Sun, Xinwei Zhang.
Oncotarget, 2016 Dec 16; 8(2). PMID: 27974689    Free PMC article.
Highly Cited. Review.
PD-L1 Expression and Combined Status of PD-L1/PD-1-Positive Tumor Infiltrating Mononuclear Cell Density Predict Prognosis in Glioblastoma Patients.
Jiheun Han, Yongkil Hong, Youn Soo Lee.
J Pathol Transl Med, 2016 Dec 19; 51(1). PMID: 27989100    Free PMC article.
Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report.
Hong Li, Weijie Ma, +7 authors, Tianhong Li.
J Hematol Oncol, 2017 Mar 02; 10(1). PMID: 28245875    Free PMC article.
Blocking the PD-1/PD-L1 pathway in glioma: a potential new treatment strategy.
Song Xue, Man Hu, Veena Iyer, Jinming Yu.
J Hematol Oncol, 2017 Apr 09; 10(1). PMID: 28388955    Free PMC article.
Aspirin Use and Colorectal Cancer Survival According to Tumor CD274 (Programmed Cell Death 1 Ligand 1) Expression Status.
Tsuyoshi Hamada, Yin Cao, +25 authors, Shuji Ogino.
J Clin Oncol, 2017 Apr 14; 35(16). PMID: 28406723    Free PMC article.
Highly Cited.
Expression of PD-L1 and prognosis in breast cancer: a meta-analysis.
Minghui Zhang, Houbin Sun, +4 authors, Qingyuan Zhang.
Oncotarget, 2017 Apr 22; 8(19). PMID: 28430626    Free PMC article.
Highly Cited.
The prognostic role of immune checkpoint markers programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) in a large, multicenter prostate cancer cohort.
Nora Ness, Sigve Andersen, +8 authors, Elin Richardsen.
Oncotarget, 2017 May 04; 8(16). PMID: 28460462    Free PMC article.
Type Iγ phosphatidylinositol phosphate kinase regulates PD-L1 expression by activating NF-κB.
Junli Xue, Chunhua Chen, +5 authors, Kun Ling.
Oncotarget, 2017 May 04; 8(26). PMID: 28465490    Free PMC article.
Mesenchymal Stromal Cells: What Is the Mechanism in Acute Graft-Versus-Host Disease?
Neil Dunavin, Ajoy Dias, Meizhang Li, Joseph McGuirk.
Biomedicines, 2017 Jul 04; 5(3). PMID: 28671556    Free PMC article.
The Challenge for Development of Valuable Immuno-oncology Biomarkers.
Janice M Mehnert, Arta M Monjazeb, +3 authors, Lyndsay N Harris.
Clin Cancer Res, 2017 Sep 03; 23(17). PMID: 28864725    Free PMC article.
Programmed cell death ligand 1 cut-point is associated with reduced disease specific survival in resected pancreatic ductal adenocarcinoma.
Basile Tessier-Cloutier, Steve E Kalloger, +6 authors, David F Schaeffer.
BMC Cancer, 2017 Sep 06; 17(1). PMID: 28870260    Free PMC article.
PD-L1 and intratumoral immune response in breast cancer.
Zhi-Qiang Wang, Katy Milne, +3 authors, Peter H Watson.
Oncotarget, 2017 Sep 09; 8(31). PMID: 28881675    Free PMC article.
Adverse prognostic value of PD-L1 expression in primary resected pulmonary squamous cell carcinomas and paired mediastinal lymph node metastases.
Manuel D Keller, Christina Neppl, +4 authors, Sabina Berezowska.
Mod Pathol, 2017 Sep 09; 31(1). PMID: 28884747
Combined prognostic effect of PD-L1 expression and immunoscore in microsatellite-unstable advanced gastric cancers.
Kyung-Ju Kim, Han Kwang Yang, Woo Ho Kim, Gyeong Hoon Kang.
Oncotarget, 2017 Sep 25; 8(35). PMID: 28938605    Free PMC article.
Tumor-infiltrating CD8+ lymphocytes predict different clinical outcomes in organ- and non-organ-confined urothelial carcinoma of the bladder following radical cystectomy.
Shiqiang Zhang, Jun Wang, Xinyu Zhang, Fangjian Zhou.
PeerJ, 2017 Oct 19; 5. PMID: 29043112    Free PMC article.
Programmed death ligand-1 and MET co-expression is a poor prognostic factor in gastric cancers after resection.
Mi Jung Kwon, Kab-Choong Kim, +8 authors, Kyueng-Whan Min.
Oncotarget, 2017 Nov 16; 8(47). PMID: 29137273    Free PMC article.
Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway.
Rosemarie Tremblay-LeMay, Nasrin Rastgoo, Hong Chang.
J Hematol Oncol, 2018 Mar 28; 11(1). PMID: 29580288    Free PMC article.
TIME (Tumor Immunity in the MicroEnvironment) classification based on tumor CD274 (PD-L1) expression status and tumor-infiltrating lymphocytes in colorectal carcinomas.
Tsuyoshi Hamada, Thing Rinda Soong, +28 authors, Shuji Ogino.
Oncoimmunology, 2018 Jun 15; 7(7). PMID: 29900052    Free PMC article.
Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1.
Yu-Tzu Tai, Shih-Feng Cho, Kenneth C Anderson.
Front Immunol, 2018 Aug 28; 9. PMID: 30147691    Free PMC article.
Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma.
Diwakar Davar, Hong Wang, +16 authors, Hassane M Zarour.
J Clin Oncol, 2018 Oct 26;. PMID: 30359157    Free PMC article.
PHA eludes macrophage suppression to activate CD8+ T cells.
Yelizavet D Lomakova, Jennifer Londregan, +3 authors, James E Riggs.
Immunobiology, 2018 Nov 18; 224(1). PMID: 30446337    Free PMC article.
Increased CD8 Tumor Infiltrating Lymphocytes in Colorectal Cancer Microenvironment Supports an Adaptive Immune Resistance Mechanism of PD-L1 Expression.
Aru W Sudoyo, Antonius N Kurniawan, +7 authors, Ahmad R Utomo.
Asian Pac J Cancer Prev, 2019 Nov 25; 20(11). PMID: 31759368    Free PMC article.
Role and mechanism of programmed death-ligand 1 in hypoxia-induced liver cancer immune escape.
Qingxian Wen, Tao Han, Zijian Wang, Shulong Jiang.
Oncol Lett, 2020 Mar 29; 19(4). PMID: 32218809    Free PMC article.
PD-1/PD-L1 pathway: current researches in cancer.
Yanyan Han, Dandan Liu, Lianhong Li.
Am J Cancer Res, 2020 Apr 09; 10(3). PMID: 32266087    Free PMC article.
Hypoxia-inducible factor-1α and nuclear factor-κB play important roles in regulating programmed cell death ligand 1 expression by epidermal growth factor receptor mutants in non-small-cell lung cancer cells.
Rong Guo, Yong Li, +5 authors, Jie Wang.
Cancer Sci, 2019 Mar 08; 110(5). PMID: 30844110    Free PMC article.
PD-L1-PD-1 Pathway in the Pathophysiology of Multiple Myeloma.
Hideto Tamura, Mariko Ishibashi, Mika Sunakawa-Kii, Koiti Inokuchi.
Cancers (Basel), 2020 Apr 16; 12(4). PMID: 32290052    Free PMC article.
MicroRNA-155-5p suppresses PD-L1 expression in lung adenocarcinoma.
Jiansheng Huang, Qiaoyou Weng, +8 authors, Jiansong Ji.
FEBS Open Bio, 2020 Apr 03; 10(6). PMID: 32237066    Free PMC article.
Prognostic perspectives of PD-L1 combined with tumor-infiltrating lymphocytes, Epstein-Barr virus, and microsatellite instability in gastric carcinomas.
Euno Choi, Mee Soo Chang, +12 authors, Seung Chul Heo.
Diagn Pathol, 2020 Jun 06; 15(1). PMID: 32498695    Free PMC article.
Recombinant Expression and Purification of Extracellular Domain of the Programmed Cell Death Protein Receptor.
Adish Zhansaya, Mukantayev Kanatbek, +6 authors, Ramankulov Yerlan.
Rep Biochem Mol Biol, 2020 Jun 26; 8(4). PMID: 32582792    Free PMC article.
Integrating the Tumor Microenvironment into Cancer Therapy.
Sabina Sanegre, Federico Lucantoni, +3 authors, Tomás Álvaro Naranjo.
Cancers (Basel), 2020 Jul 01; 12(6). PMID: 32599891    Free PMC article.
The tumor immune microenvironment transcriptomic subtypes of colorectal cancer for prognosis and development of precise immunotherapy.
Yun-Qiang Tang, Tu-Feng Chen, +8 authors, Jun Huang.
Gastroenterol Rep (Oxf), 2020 Nov 10; 8(5). PMID: 33163194    Free PMC article.
Programmed cell death-ligand 1 expression in stromal immune cells is a marker of breast cancer outcome.
Mineui Hong, Jeong Won Kim, +2 authors, Soo Kyung Ahn.
J Cancer, 2020 Nov 17; 11(24). PMID: 33193888    Free PMC article.
B7-H1 Promotes the Functional Effect of Human Gingiva-Derived Mesenchymal Stem Cells on Collagen-Induced Arthritis Murine Model.
Wenbin Wu, Ze Xiu Xiao, +6 authors, Song Guo Zheng.
Mol Ther, 2020 Jul 25; 28(11). PMID: 32707035    Free PMC article.
A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization.
Miguel F Sanmamed, Lieping Chen.
Cell, 2018 Oct 06; 175(2). PMID: 30290139    Free PMC article.
Highly Cited. Review.
Preclinical platform for long-term evaluation of immuno-oncology drugs using hCD34+ humanized mouse model.
Nahee Park, Kamal Pandey, +10 authors, Yong Wha Moon.
J Immunother Cancer, 2020 Nov 27; 8(2). PMID: 33239416    Free PMC article.
Prognostic Role of Immune Markers in Triple Negative Breast Carcinoma.
Hulya Sahin Ozkan, Mustafa Umit Ugurlu, Perran Fulden Yumuk, Handan Kaya.
Pathol Oncol Res, 2020 Jul 19; 26(4). PMID: 32681436
Prognostic Value of Soluble Programmed Cell Death Ligand-1 (sPD-L1) in Various Cancers: A Meta-analysis.
Xiaoyang Li, Yu Zheng, Fei Yue.
Target Oncol, 2020 Nov 23; 16(1). PMID: 33222017
The expression of programmed death-ligand 1 in patients with invasive breast cancer.
Yi Meng, Hongyan Wu, Yongzhong Yao, Rong Li.
Gland Surg, 2021 Jan 16; 9(6). PMID: 33447561    Free PMC article.
Mechanisms of Pharmaceutical Therapy and Drug Resistance in Esophageal Cancer.
Chengyi Mao, Xiaoxi Zeng, +5 authors, Yong Yuan.
Front Cell Dev Biol, 2021 Mar 02; 9. PMID: 33644048    Free PMC article.
Expression of PDL1 and Her2neu in Gastric and Gastroesophageal Junction Adenocarcinoma.
Animesh Saurabh, Vandana Raphael, +3 authors, Umesh Das.
Indian J Surg Oncol, 2021 May 18; 12(Suppl 1). PMID: 33994740    Free PMC article.
Impact of PD-L1 and PD-1 Expression on the Prognostic Significance of CD8+ Tumor-Infiltrating Lymphocytes in Non-Small Cell Lung Cancer.
Enrico Munari, Marcella Marconi, +16 authors, Giuseppe Bogina.
Front Immunol, 2021 Jun 15; 12. PMID: 34122444    Free PMC article.
First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma.
Antoine Italiano, Philippe A Cassier, +18 authors, Victor Moreno.
Cancer Immunol Immunother, 2021 Jul 04; 71(2). PMID: 34216247    Free PMC article.
miR-105-5p regulates PD-L1 expression and tumor immunogenicity in gastric cancer.
Christos Miliotis, Frank J Slack.
Cancer Lett, 2021 Jun 08; 518. PMID: 34098061    Free PMC article.
Correlation between schistosomiasis and CD8+ T cell and stromal PD-L1 as well as the different prognostic role of CD8+ T cell and PD-L1 in schistosomal-associated colorectal cancer and non-schistosomal-associated colorectal cancer.
Weixia Wang, Hongyan Jing, +10 authors, Limei Wang.
World J Surg Oncol, 2021 Nov 09; 19(1). PMID: 34743724    Free PMC article.
Emerging Role of PD-1/PD-L1 Inhibitors in Chronic Liver Diseases.
Vishakha Singh, Amit Khurana, +3 authors, Ralf Weiskirchen.
Front Pharmacol, 2022 Jan 11; 12. PMID: 35002724    Free PMC article.
PD-L1 expression and patient outcomes in gastrointestinal neuroendocrine neoplasm: a meta-analysis.
Woojoo Lee, Min-Ju Kim, Younghee Choi, Hyunchul Kim.
Transl Cancer Res, 2022 Feb 05; 10(5). PMID: 35116539    Free PMC article.
High programmed death-ligand 1 expression is a poor prognostic indicator for esophageal squamous cell carcinoma and is correlated with two-field lymph node metastasis.
Mingqiang Liang, Fengqiang Yu, +5 authors, Chun Chen.
Transl Cancer Res, 2020 Apr 01; 9(4). PMID: 35117606    Free PMC article.
Loss of TSC1/TSC2 sensitizes immune checkpoint blockade in non-small cell lung cancer.
Qingyuan Huang, Fei Li, +17 authors, Kwok-Kin Wong.
Sci Adv, 2022 Feb 05; 8(5). PMID: 35119931    Free PMC article.
Evaluation of MMR Status and PD-L1 Expression Using Specimens Obtained by EUS-FNB in Patients with Pancreatic Ductal Adenocarcinoma (PDAC).
Alina Constantin, Vlad Iovănescu, +5 authors, Adrian Săftoiu.
Diagnostics (Basel), 2022 Feb 26; 12(2). PMID: 35204385    Free PMC article.
Diagnostic Performance of PD-L1 versus PD-1 Expression in Circulating CD20 Cells in Diffuse Large B-Cell Lymphoma.
Manal Mohamed Saber.
Antibodies (Basel), 2022 Mar 01; 11(1). PMID: 35225873    Free PMC article.
Differential expression of PD‑L1 and PD‑L2 is associated with the tumor microenvironment of TILs and M2 TAMs and tumor differentiation in non‑small cell lung cancer.
Ryota Sumitomo, Cheng-Long Huang, +2 authors, Hiroshi Date.
Oncol Rep, 2022 Feb 17; 47(4). PMID: 35169863    Free PMC article.
Role of Hypoxia in the Interferon Response.
Esther Arnaiz, Adrian L Harris.
Front Immunol, 2022 Mar 08; 13. PMID: 35251003    Free PMC article.
Uncovering Pharmacological Opportunities for Cancer Stem Cells-A Systems Biology View.
Cristina Correia, Taylor M Weiskittel, +4 authors, Hu Li.
Front Cell Dev Biol, 2022 Apr 02; 10. PMID: 35359437    Free PMC article.
Phagocytosis checkpoints as new targets for cancer immunotherapy.
Mingye Feng, Wen Jiang, +3 authors, Irving L Weissman.
Nat Rev Cancer, 2019 Aug 30; 19(10). PMID: 31462760    Free PMC article.
Highly Cited. Review.